Renal · Urology
The facts most likely to be tested
Overactive bladder is defined by urinary urgency occurring with or without urge incontinence, usually accompanied by frequency and nocturia.
The primary pathophysiology involves detrusor overactivity, characterized by involuntary bladder contractions during the filling phase.
First-line management for all patients is behavioral therapy, including bladder training, pelvic floor muscle exercises, and fluid management.
Antimuscarinic agents (e.g., oxybutynin, tolterodine) are the first-line pharmacologic treatment, though they are limited by anticholinergic side effects like dry mouth and constipation.
Beta-3 adrenergic agonists (e.g., mirabegron) serve as an alternative to antimuscarinics and do not cause the same anticholinergic side effects.
Urinalysis is the mandatory initial diagnostic test to rule out urinary tract infection, hematuria, or glycosuria as secondary causes of symptoms.
Refractory cases may be treated with onabotulinumtoxinA injections into the detrusor muscle or sacral neuromodulation.
Vignette unlocked
A 68-year-old woman presents to the clinic complaining of a sudden, intense need to void that is difficult to defer, resulting in involuntary leakage of urine several times a day. She reports voiding 10 times during the day and waking up 3 times at night to urinate. She denies dysuria, hematuria, or pelvic pressure. A urinalysis is negative for nitrites, leukocyte esterase, and blood. Physical examination reveals no evidence of pelvic organ prolapse or urethral hypermobility.
What is the most appropriate initial management for this patient?
Behavioral therapy (bladder training and fluid management)
The patient's presentation of urgency, frequency, and nocturia is classic for overactive bladder; behavioral therapy is the first-line treatment before initiating pharmacotherapy.
Full handout
High yield triage
Etiology / Epidemiology
Common in aging populations and postmenopausal women due to detrusor overactivity.
Clinical Manifestations
Characterized by urgency, frequency, and nocturia without evidence of UTI.
Diagnosis
Diagnosis is clinical; Urodynamic testing is the gold standard for complex cases.
Treatment
First-line is Behavioral therapy (bladder training); pharmacotherapy uses Oxybutynin.
Prognosis
Chronic condition; Quality of life impact is the primary clinical concern.
Full handout
Epidemiology & Etiology
Prevalence increases significantly with age, affecting both sexes but more frequently reported in postmenopausal women. Etiology is often idiopathic, though it may be exacerbated by obesity, diabetes mellitus, and pelvic floor dysfunction. It is a clinical diagnosis of exclusion.
Pertinent Anatomy
The detrusor muscle is the primary effector of bladder emptying. In OAB, involuntary contractions occur during the filling phase, overriding the inhibitory signals from the pontine micturition center.
Pathophysiology
The condition results from detrusor overactivity, where the bladder muscle contracts prematurely during filling. This is often linked to increased acetylcholine release at muscarinic receptors. The loss of central nervous system inhibition leads to the classic urgency symptoms.
Clinical Manifestations
Patients present with urinary urgency, frequency (>8 voids/day), and nocturia. Red flags include hematuria, recurrent UTIs, or pelvic pain, which necessitate ruling out malignancy or interstitial cystitis. Physical exam is typically normal, but must exclude pelvic organ prolapse.
Diagnosis
Diagnosis is primarily clinical based on history and voiding diaries. Urodynamic testing is the gold standard for confirming detrusor overactivity in refractory cases. Always perform a urinalysis to rule out infection or glycosuria.
Treatment
First-line therapy is Behavioral modification (bladder training, fluid management). Pharmacotherapy utilizes Oxybutynin (antimuscarinic) to inhibit detrusor contractions. Contraindications for antimuscarinics include narrow-angle glaucoma and urinary retention. Refractory cases may require Botulinum toxin injections or sacral nerve stimulation.
Prognosis
OAB is a chronic, manageable condition rather than a curable disease. Quality of life scores are the primary metric for success. Monitor for urinary retention in patients on long-term anticholinergic therapy.
Differential Diagnosis
UTI: presence of pyuria and bacteriuria
Diabetes Mellitus: polyuria due to osmotic diuresis
Stress Incontinence: leakage with increased intra-abdominal pressure
Interstitial Cystitis: associated with chronic pelvic pain
Bladder Cancer: painless gross hematuria